DuPont Spinning Off Rx Business As Cozaar Profit-Share Trigger Nears
Executive Summary
DuPont's handling of the profit-sharing agreement for Cozaar is a central consideration in the valuing of the company's planned prescription drug spin-off.
You may also be interested in...
DuPont Pharma Has "A Number Of Bidders"; Company Still Considering IPO
DuPont has had several companies express interest in purchasing its pharmaceutical business, DuPont Pharmaceuticals Chairman Richard DeSchutter told an April 11 meeting with securities analysts.
DuPont Pharma Has "A Number Of Bidders"; Company Still Considering IPO
DuPont has had several companies express interest in purchasing its pharmaceutical business, DuPont Pharmaceuticals Chairman Richard DeSchutter told an April 11 meeting with securities analysts.
GlaxoSmithKline Is Mouthful But Still Hungry: Is Next Course Japanese?
GlaxoSmithKline's acquisition strategy will concentrate on medium-sized pharmaceutical and biotech companies with a pipeline, CEO J.P. Garnier told analysts during a Feb. 22 meeting in London.